Brief: Sequana Medical Announces DSMB Approval To Start Randomized MOJAVE Cohort

Sequana Medical NV

23/01/2024 06:05

Jan 23 (Reuters) - Sequana Medical NV  SEQUA.BR :
    * SEQUANA MEDICAL ANNOUNCES DSMB APPROVAL TO START
RANDOMIZED
MOJAVE COHORT - US PHASE 1/2A STUDY OF DSR® 2.0 FOR TREATMENT OF
HEART FAILURE
    * FIRST PATIENT ENROLLED IN RANDOMIZED CONTROLLED COHORT
EXPECTED
IN Q1 2024
    * DSMB(I) RATES DSR 2.0 AS SAFE FOLLOWING REVIEW OF DATA
FROM
NON-RANDOMIZED COHORT
    * DATA FROM NON-RANDOMIZED COHORT CONFIRMS DRAMATIC
IMPROVEMENT IN
DIURETIC RESPONSE AND AT LEAST 95% REDUCTION IN LOOP DIURETIC
REQUIREMENTS UP TO ALMOST FOUR MONTHS AFTER LAST DSR THERAPY
    * INTERIM DATA ARE PLANNED FOR H2 2024

Source text for Eikon:  ID:nGNX37LYxW 
Further company coverage:  SEQUA.BR 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))